PAXMAN publishes newsletter on its new CIPN indication and the double win at the EEF Future Manufacturing Awards
Today, PAXMAN publishes the February 2019 issue of its newsletter aimed at shareholders, investors and other interested parties.In this issue, PAXMAN’s CEO comments on the company’s new project to develop a cooling device for preventing chemotherapy-induced nerve damage in hands and feet (CIPN) with National University Hospital, Singapore. Additionally, a video is included from PAXMAN’s double win at this year’s EEF Future Manufacturing Awardsin London. To read the newsletter, and subscribe to receive upcoming issues, follow this link: http://bit.ly/